

# Technical Data Sheet

## InVivoMAb anti-mouse BTLA (CD272)



**Attention:** Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

### Lot Specific Information

Lot Number: Lot Specific\*  
Volume: Lot Specific\*  
Concentration: Lot Specific\* (generally 4 to 11 mg/ml) \*  
Total Protein: Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

### Product Information

Catalog Number: BE0304  
Clone: 6F7  
Isotype: Mouse IgG1,  $\kappa$   
Recommended Isotype Control(s): InVivoMAb mouse IgG1 isotype control, unknown specificity  
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer  
Immunogen: Ig domain of C57BL/6 mouse BTLA  
Reported Applications: *in vivo* BTLA+ B cell and CD4 T cell depletion\*  
Flow cytometry  
\*see description for details  
Formulation: PBS, pH 7.0  
Contains no stabilizers or preservatives  
Endotoxin: <2EU/mg (<0.002EU/ $\mu$ g)  
Determined by LAL gel clotting assay  
Purity: >95%  
Determined by SDS-PAGE  
Sterility: 0.2  $\mu$ m filtration  
Production: Purified from cell culture supernatant in an animal-free facility  
Purification: Protein G  
RRID: [AB\\_2721033](https://abnova.com/AB_2721033)  
Molecular Weight: 150 kDa

### Description

The 6F7 monoclonal antibody reacts with mouse B- and T-lymphocyte attenuator (BTLA) also known as CD272. BTLA is an Ig superfamily member which is expressed on B cells, T cells, macrophages, dendritic cells, NK cells, and NKT cells. Like PD-1 and CTLA-4, BTLA interacts with a B7 homolog, B7-H4. However, unlike PD-1 and CTLA-4, BTLA displays T cell inhibition via interaction with tumor necrosis family receptors, not just the B7 family of cell surface receptors. BTLA is a ligand for herpes virus entry mediator (HVEM). BTLA-HVEM complexes have been shown to negatively regulate T cell immune responses. There are conflicting reports concerning the activity of the 6F7 antibody. In some cases, the antibody is reported to deplete BTLA+ B and CD4 T cells while in others the antibody is reported as having agonistic activity. See the references for details.

### Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

### Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

## Application References

For a complete list of references, visit [https://bioxcell.com/be0304?bxcs=9k1b3a#tab\\_references](https://bioxcell.com/be0304?bxcs=9k1b3a#tab_references) or scan the QR code below.



---

**Bio X Cell, LLC**

<https://bioxcell.com>

+1-866-787-3444

[customerservice@bioxcell.com](mailto:customerservice@bioxcell.com)

*Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.*

*Not for resale.*

**Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC**